Tonix Pharmaceuticals, Inc.
Tonix Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines and vaccines for central nervous system disorders, immunology, infectious diseases, and rare diseases. They have a robust pipeline ranging from preclinical to NDA submission, including FDA-approved products for acute migraine. The company emphasizes scientific advancement, strategic collaborations, and a mission to improve global population health.
Industries
Nr. of Employees
small (1-50)
Tonix Pharmaceuticals, Inc.
Tonix Corporate Headquarters
Patents
Products
Sumatriptan subcutaneous injection (3 mg) for acute migraine
Marketed acute migraine therapy delivered by injection for adults.
Sumatriptan nasal spray (10 mg) for acute migraine
Marketed acute migraine therapy delivered via intranasal spray for adults.
Sumatriptan subcutaneous injection (3 mg) for acute migraine
Marketed acute migraine therapy delivered by injection for adults.
Sumatriptan nasal spray (10 mg) for acute migraine
Marketed acute migraine therapy delivered via intranasal spray for adults.
Services
Digital patient-facing platform providing educational resources, telehealth access to specialists and e-prescription facilitation for acute migraine care.
Digital patient-facing platform providing educational resources, telehealth access to specialists and e-prescription facilitation for acute migraine care.
Expertise Areas
- Clinical trial management
- Vaccine development and manufacturing
- Therapeutic biologics (monoclonal antibodies)
- Central nervous system therapeutics
Key Technologies
- Live-virus vaccine vectors
- Monoclonal antibody discovery
- Sublingual small-molecule formulation
- Intranasal peptide/neuroactive delivery
News & Updates
May 22, 2025
May 12, 2025
May 2024 presentation on acute stress disorder.
March 2024 research presentation.
May 22, 2025
May 12, 2025
May 2024 presentation on acute stress disorder.
March 2024 research presentation.